In June 2014, the U.S. Food and Drug Administration (FDA) approved a new formulation of the Afrezza inhaled insulin powder to act as prandial insulin requirements for non-smoking adults with diabetes who are free of pulmonary disease. This evidence concerns the gene INS and diabetes mellitus.